Emocog

Emocog develops and commercializes digital therapeutics software focused on early intervention and management of mild cognitive impairment and subjective cognitive decline. Its flagship product, Cogthera, uses AI-driven personalized regimens to deliver daily testing and training that aim to slow or prevent progression to dementia. The company’s solutions are supported by over two decades of research with multiple peer-reviewed publications. Cogthera has been designated an innovative medical device in South Korea and clinical studies support its efficacy for memory enhancement across eight core domains. Expansion into international markets such as Germany via the DiGA fast track process is underway.